TOXICITIES DUE TO CHEMOTHERAPY IN LUNG CANCER

Year 2012, Volume: 26 Issue: 3, 165 - 171, 01.12.2012

Melike Kazancı Cenk Kıraklı Ahmet Emin Erbaycu Salih Zeki Güçlü

Abstract

The aim of this study was to evaluate the chemotherapy combination choices and short term toxicities in lung cancer patients who had first line chemotherapy between 2004 and 2010. Patients were enrolled retrospectively. Age, gender, disease stage, performance status (ECOG score), histologic type of the tumour, chemotherapy choice and toxicities were recorded. Evaluation of the toxicites were done according to the CTCAE criteria. A total number of 803 patients were included in the study. The most common tumour types were nonsmall cell, squamous, adenocarcinoma and small cell carcinoma. The most common choice of chemotherapy combinations were Cisplatin+ Gemsitabine, Cisplatin+Etoposide and Cisplatin+ Docetaxel respectively. When all the chemotherapy regimes were evaluated, the most common toxicites were hematologic ones such as anemia and neutropenia. No side effects were observed in 40% of patients who had Cisplatin based combinations and 39% of patients who had Carboplatin based combinations. Short term toxicites such as anemia, neutropenia and nausea must be kept in mind in lung cancer patients who will have chemotherapy. Benefit and risks should be analysed carefully and selection of chemotherapy combinations and patients should be done according to these toxiciy profiles.

Keywords

Lung cancer, chemotherapy, toxicity

AKCİĞER KANSERİNDE UYGULANAN KEMOTERAPİYE BAĞLI TOKSİSİTE

Abstract

Bu çalışmanın amacı, 2004-2010 yılları arasında akciğer kanseri nedeniyle birinci hat kemoterapi alan olgularda tercih edilen kemoterapi kombinasyonlarını ve gelişebilecek kısa dönem yan etkileri ortaya koymaktır. Hastalar retrospektif olarak çalışmaya alındı. Yaş, cinsiyet, hastalık evresi, performans düzeyi (ECOG skoru), tümör hücre tipi, planlanan kemoterapi uygulaması, birinci kür sonrası oluşan toksisiteleri kaydedildi. Toksisite değerlendirmeleri CTCAE kriterlerine göre yapıldı. Çalışmaya toplam 803 hasta alındı. En sık rastlanan tümör hücre tipleri, küçük hücreli dışı, skuam öz, adenokarsinom ve küçük hücreli karsinomdu. En fazla tercih edilen kemoterapi kombinasyon rejimleri olarak da Cisplatin+Gemsitabine, Cisplatin+Etoposide ve Cisplatin+Dosetaksel göze çarpmaktaydı. Bütün rejimler göz önüne alındığında en sık rastlanan toksisiteler anemi ve nötropeni gibi hematolojik toksisitelerdi. Cisplatin bazlı rejim alanların %40'ında, Carboplatin bazlı rejim alanların da %39'unda yan etki gözlenmedi. Akciğer kanserli hastalarda kemoterapi uygulamaları sırasında, özellikle kısa dönem toksisiteler açısından anemi, nötropeni ve bulantı-kusma akılda tutulmalıdır. Kemoterapi uygulanacak hastaların seçimi sırasında bu yan etki profillerine göre fayda risk analizi yapılmalı ve ilaç kombinasyonları buna göre oluşturulmalıdır.

Keywords

Akciğer kanseri, kemoterapi, toksisite

References

• 1. Abal› H, Zengin N. Akci¤er kanseri kemoterapisinde miyelotoksisite yönetimi. Gülhan M, Turay ÜY (eds). Akci¤er Kanserinde Destek Tedavisi. Sentez Matbaac›l›k, Ankara, 2009; 155-61.
• 2. Yurdakul AS. Kemoterapiye ba¤l› bulant› ve kusmalarda yaklafl›m. Akci¤er ve Plevra Maligniteleri Tedavisi. Göksel T, Özlü T (eds). Sentez Matbaac›l›k, Ankara, 2008; 184-95.
• 3. WHO Toxicity Grading Scale for Determining The Severity of Adverse Events. http://www. icssc.org/Documents/Resources/ AEManual2003AppendicesFebruary_06_200 3%20final.pdf.
• 4. Helbekkmo N, Aasebo U, Sundstrom SH, et al. Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 2008; 62(2): 253-60.
• 5. Jensen LH, Osterlind CK. Rytter, Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008; 62(1): 85-91.
• 6. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 2007; 25(12): 1553-61.
• 7. Gebbia V, Galetta D, Lorusso V, et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 2008; 61(3): 369-77.
• 8. Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97(3): 283-9.
• 9. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-smallcell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99 (11): 847-57.
• 10. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92.
• 11. Casas FN. Vinolas, Toxicity of small cell lung cancer treatment. Hematol Oncol Clin North Am 2004; 18(2): 461-81.
• 12. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV nonsmall cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41(3): 321-31.
• 13. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352(25): 2589-97.
• 14. Hardy D, Cormier JN, Xing Y, et al. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol 2010; 5(1): 90-8.